1. Home
  2. Media
  3. News
  4. Bioiberica to begin a clinical trial to ratify the effects of Impromune® in dogs under standard leishmaniosis treatment

Bioiberica to begin a clinical trial to ratify the effects of Impromune® in dogs under standard leishmaniosis treatment

28 Feb 2019
Companion Animal Health
  • This is a two-year long clinical, multicenter, randomized placebo-controlled trial, involving more than 100 dogs of various breeds
  • Impromune®, a dietary supplement based on nucleotides and AHCC, has already proved its benefits in two prior studies published by Veterinary Parasitology and Parasites & Vectors
  • Canine leishmaniosis is a zoonotic parasitic disease that can be lethal for dogs as well as humans. It is known to exist in more than 50 countries

Bioibérica Companion Animal Health announced the launch of the GALILEI study (doG triAL with Impromune in LEIshmania), a two-year long clinical, multicenter, randomized, placebo-controlled trial involving more than 100 dogs of various breeds suffering from leishmaniosis, recruited at various veterinary hospitals in Spain and Portugal. The trial will study the effects of adding the Impromune® food supplement to the dogs’ diet while following a standard treatment for canine leishmaniosis. The objective is to find out whether the dogs receiving this supplement will suffer a smaller number of relapses.

Impromune® is a food supplement developed by Bioiberica, based on nucleotides and active hexose correlated compound (AHCC), which optimizes the immune system’s response in cats and dogs, thus achieving a higher efficiency both in the animals’ innate as well as in the adaptive response. This product has already proved its benefits in two prior studies published by Veterinary Parasitology[1] and Parasites & Vectors[2]. “The addition of Impromune could become an asset to achieve a better immune response in leishmaniosis dogs, thus improving the efficacy of the standard treatment, as well as reducing their secondary effects if we find out that we can adjust the medication’s dosage or frequency of use”, explained Dr. Sergi Segarra, R&D Project Leader Animal Health at Bioiberica.

Canine leishmaniosis is a zoonotic parasitic disease that can be lethal for dogs as well as humans. It is known to exist in more than 50 countries and is transmitted by the sting of a flying insect, the sandfly. The response of the immune system of the affected individuals is a key factor to determine how these patients will evolve, as well as their prognosis. “This is why the scientific community is contemplating the idea of using immune system modulation as a strategy for the management of this disease, and Bioiberica’s R&D department is willing to keep investigating along these lines,” remarked Dr. Segarra.

 


[1]  http://www.sciencedirect.com/science/article/pii/S0304401717301760

Segarra, S., Miró, G., Montoya, A., Pardo-Marín, L., Boqué, N., Ferrer, L., & Cerón, J. (2017). Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis. VeterinaryParasitology239, 50-56. 

[2] https://www.ncbi.nlm.nih.gov/pubmed/29467015

Segarra,S., Miró, G., Montoya, A., Pardo-Marín, L., Teichenné, J., Ferrer, L., Cerón, JJ: (2018). Prevention of disease progression in Leishmaniainfantum-infected dogs with dietary nucleotides and active hexose correlated compound.Parasit&Vectors. 2018 Feb 21;11(1):103. doi: 10.1186/s13071-018-2705-z.